Across TCGA pan-cancer cohorts, NOVA2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NOVA2 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher NOVA2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NOVA2 expression acts as an unfavorable survival marker.
COAD, ESCA, and UCS are the cancer types where NOVA2 Mutation most reproducibly stratifies survival.